老药新用抗击新冠肺炎  

Drug Repurposing Strategy for the Treatment of COVID-19

作　　者：胡洪果 李艳梅[1] HU Hong-Guo;LI Yan-Mei(Department of Chemistry,Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology Ministry of Education,Tsinghua University,Beijing 100084,China)

机构地区：[1]清华大学化学系生命有机磷化学及化学生物学教育部重点实验室,北京100084

出　　处：《化学教育（中英文）》2021年第2期1-5,共5页Chinese Journal of Chemical Education

基　　金：国家重点研发计划(2018YFA0507600);基金委-面上项目(21672126)。

摘　　要：新冠肺炎疫情爆发以来,临床上通过老药新用的策略发展小分子药物,以用于治疗新冠肺炎。在短时间内迅速从抗病毒、抗炎药物中发现能够用于新冠治疗的药物,如洛匹那韦/利托那韦、磷酸氯喹等。结合几款典型的药物,浅析它们在抗击新冠肺炎中的应用。Since the outbreak of COVID-19,small-molecule drugs have been developed for the treatment of COVID-19 through drug repurposing strategy.Antiviral and anti-inflammatory drugs such as lopinavir/ritonavir and chloroquine phosphate were timely found to be suitable for the treatment of COVID-19.This article reviews the application of several typical drugs in the fight against COVID-19.

关 键 词：新冠病毒 新冠肺炎 小分子药物 老药新用 

分 类 号：R563.1[医药卫生—呼吸系统]